Muhammad Shurafa

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

Alan F. List, Kenneth J. Kopecky, Cheryl L. Willman et al. · Blood · 2001 · 418 citations · Full text

Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)

Madhav V. Dhodapkar, Joth Jacobson, Morie A. Gertz et al. · Blood · 2001 · 147 citations · Full text

Clinical significance of Y chromosome loss in hematologic disease

Anne E. Wiktor, Benjamin A. Rybicki, Zhe Si Piao et al. · Genes Chromosomes and Cancer · 2000 · 115 citations

Down Syndrome, Cytogenetics, Genetic Disorder +8

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Mary Varterasian, Ramzi M. Mohammad, Muhammad Shurafa et al. · PubMed · 2000 · 97 citations

Relapsed Low-grade Non-hodgkin, Immunology, Pathology +16

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617

Thomas R. Chauncey, Cathryn Rankin, Jeanne E. Anderson et al. · Leukemia Research · 2000 · 56 citations

Hematological Malignancy, Oncology, Medicine +9